Abstract
Introduction: We sought to determine if our previously validated proteomic profile for detecting Alzheimer's disease would detect Parkinson's disease (PD) and distinguish PD from other neurodegenerative diseases. Methods: Plasma samples were assayed from 150 patients of the Harvard Biomarkers Study (PD, n = 50; other neurodegenerative diseases, n = 50; healthy controls, n = 50) using electrochemiluminescence and Simoa platforms. Results: The first step proteomic profile distinguished neurodegenerative diseases from controls with a diagnostic accuracy of 0.94. The second step profile distinguished PD cases from other neurodegenerative diseases with a diagnostic accuracy of 0.98. The proteomic profile differed in step 1 versus step 2, suggesting that a multistep proteomic profile algorithm to detecting and distinguishing between neurodegenerative diseases may be optimal. Discussion: These data provide evidence of the potential use of a multitiered blood-based proteomic screening method for detecting individuals with neurodegenerative disease and then distinguishing PD from other neurodegenerative diseases.
| Original language | English |
|---|---|
| Pages (from-to) | 374-382 |
| Number of pages | 9 |
| Journal | Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring |
| Volume | 11 |
| DOIs | |
| State | Published - Dec 2019 |
Keywords
- Blood biomarkers
- Diagnostic accuracy
- Parkinson's disease
- Precision medicine
- Proteomics
Fingerprint
Dive into the research topics of 'Potential two-step proteomic signature for Parkinson's disease: Pilot analysis in the Harvard Biomarkers Study'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
Potential two-step proteomic signature for Parkinson's disease : Pilot analysis in the Harvard Biomarkers Study. / O'Bryant, Sid E.; Edwards, Melissa; Zhang, Fan et al.
In: Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, Vol. 11, 12.2019, p. 374-382.Research output: Contribution to journal › Article › peer-review
TY - JOUR
T1 - Potential two-step proteomic signature for Parkinson's disease
T2 - Pilot analysis in the Harvard Biomarkers Study
AU - O'Bryant, Sid E.
AU - Edwards, Melissa
AU - Zhang, Fan
AU - Johnson, Leigh A.
AU - Hall, James
AU - Kuras, Yuliya
AU - Scherzer, Clemens R.
N1 - Funding Information: The authors thank all study participants, their families, and friends for their support and participation and our study coordinators. C.R.S. was supported in part by the American Parkinson Disease Association and NIH grants U01NS082157 , U01NS095736 , U01NS100603 , and R01AG057331 . HBS was supported by the APDA Advanced Center for Parkinson's Disease Research, Harvard NeuroDiscovery Center , NINDS U01NS082157 , U01NS100603 , and the Massachusetts Alzheimer's Disease Research Center NIA P50AG005134 . S.E.O. was supported in part by grants from the National Institute on Aging of the National Institutes of Health under award numbers R01AG054073 , R01AG051848 , R01AG058252 , and R01AG058537 . The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Funding Information: Potential Conflicts of Interest: C.R.S. has collaborated with Pfizer, OPKO, Proteome Sciences, Sanofi, and Berg Health; has consulted for Sanofi; has served as advisor to the Michael J. Fox Foundation, NIH, Department of Defense; is on the scientific advisory board of the American Parkinson Disease Association; has received funding from the NIH, the US Department of Defense, the Harvard NeuroDiscovery Center, the Michael J. Fox Foundation, and American Parkinson Disease Association. S.E.O. has multiple patents pending on precision medicine for neurodegenerative diseases; is the founding scientist for Cx Precision Medicine; and has served as a consultant to Roche Diagnostics. S.E.O. has received funding from the National Institute on Aging, Michael J. Fox Foundation, Alzheimer's Association, has multiple patents pending on precision medicine for neurodegenerative diseases; is the founding scientist for Cx Precision Medicine and has served as a consultant to Roche Diagnostics.The authors thank all study participants, their families, and friends for their support and participation and our study coordinators. C.R.S. was supported in part by the American Parkinson Disease Association and NIH grants U01NS082157, U01NS095736, U01NS100603, and R01AG057331. HBS was supported by the APDA Advanced Center for Parkinson's Disease Research, Harvard NeuroDiscovery Center, NINDS U01NS082157, U01NS100603, and the Massachusetts Alzheimer's Disease Research Center NIA P50AG005134. S.E.O. was supported in part by grants from the National Institute on Aging of the National Institutes of Health under award numbers R01AG054073, R01AG051848, R01AG058252, and R01AG058537. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The authors thank the following studies and investigators:, Harvard Biomarkers Study:, Co-Directors of the Harvard NeuroDiscovery Center: Clemens R. Scherzer, Bradley T. Hyman, Charles G. Jennings; investigators and study coordinators at the Harvard NeuroDiscovery Center: Yuliya I. Kuras, Daly Franco, Frank Zhu, Karbi Choudhury; investigators and study coordinators at the Brigham and Women's Hospital: Lewis R. Sudarsky, Michael T. Hayes, Chizoba C. Umeh, Reisa Sperling; investigators and study coordinators at the Massachusetts General Hospital: John H. Growdon, Michael A. Schwarzschild, Albert Y. Hung, Alice W. Flaherty, Deborah Blacker, Anne-Marie Wills, U. Shivraj Sohur, Vivek K. Unni, Nicte I. Mejia, Anand Viswanathan, Stephen N. Gomperts, Vikram Khurana, Mark W. Albers, Maria Allora-Palli, Alireza Atri, David Hsu, Alexandra Kimball, Scott McGinnis, Nutan Sharma, John Becker, Randy Buckner, Thomas Byrne, Maura Copeland, Bradford Dickerson, Matthew Frosch, Theresa Gomez-Isla, Steven Greenberg, James Gusella, Julius Hedden, Elizabeth Hedley-Whyte, Keith Johnson, Raymond Kelleher, Aaron Koenig, Maria Marquis-Sayagues, Gad Marshall, Sergi Martinez-Ramirez, Donald McLaren, Olivia Okereke, Elena Ratti, Christopher William, Koene Van Dij, Shuko Takeda, Anat Stemmer-Rachaminov, Jessica Kloppenburg, Catherine Munro, Rachel Schmid, Sarah Wigman, Sara Wlodarcsyk; investigators and study coordinators at the University of Ottawa: Michael G. Schlossmacher; Scientific Advisory Board member of the Massachusetts General Hospital: John H. Growdon; Scientific Advisory Board members of the Brigham and Women's Hospital: Dennis J. Selkoe and Reisa Sperling; Scientific Advisory Board member of the Harvard School of Public Health: Alberto Ascherio; Data Coordinator at the Harvard NeuroDiscovery Center: Thomas Yi; Data Coordinators at the Massachusetts General Hospital: Joseph J. Locascio and Haining Li; Biobank Management Staff at the Harvard NeuroDiscovery Center: Gabriel Stalberg and Zhixiang Liao. Potential Conflicts of Interest: C.R.S. has collaborated with Pfizer, OPKO, Proteome Sciences, Sanofi, and Berg Health; has consulted for Sanofi; has served as advisor to the Michael J. Fox Foundation, NIH, Department of Defense; is on the scientific advisory board of the American Parkinson Disease Association; has received funding from the NIH, the US Department of Defense, the Harvard NeuroDiscovery Center, the Michael J. Fox Foundation, and American Parkinson Disease Association. S.E.O. has multiple patents pending on precision medicine for neurodegenerative diseases; is the founding scientist for Cx Precision Medicine; and has served as a consultant to Roche Diagnostics. S.E.O. has received funding from the National Institute on Aging, Michael J. Fox Foundation, Alzheimer's Association, has multiple patents pending on precision medicine for neurodegenerative diseases; is the founding scientist for Cx Precision Medicine and has served as a consultant to Roche Diagnostics. Publisher Copyright: © 2019 The Authors
PY - 2019/12
Y1 - 2019/12
N2 - Introduction: We sought to determine if our previously validated proteomic profile for detecting Alzheimer's disease would detect Parkinson's disease (PD) and distinguish PD from other neurodegenerative diseases. Methods: Plasma samples were assayed from 150 patients of the Harvard Biomarkers Study (PD, n = 50; other neurodegenerative diseases, n = 50; healthy controls, n = 50) using electrochemiluminescence and Simoa platforms. Results: The first step proteomic profile distinguished neurodegenerative diseases from controls with a diagnostic accuracy of 0.94. The second step profile distinguished PD cases from other neurodegenerative diseases with a diagnostic accuracy of 0.98. The proteomic profile differed in step 1 versus step 2, suggesting that a multistep proteomic profile algorithm to detecting and distinguishing between neurodegenerative diseases may be optimal. Discussion: These data provide evidence of the potential use of a multitiered blood-based proteomic screening method for detecting individuals with neurodegenerative disease and then distinguishing PD from other neurodegenerative diseases.
AB - Introduction: We sought to determine if our previously validated proteomic profile for detecting Alzheimer's disease would detect Parkinson's disease (PD) and distinguish PD from other neurodegenerative diseases. Methods: Plasma samples were assayed from 150 patients of the Harvard Biomarkers Study (PD, n = 50; other neurodegenerative diseases, n = 50; healthy controls, n = 50) using electrochemiluminescence and Simoa platforms. Results: The first step proteomic profile distinguished neurodegenerative diseases from controls with a diagnostic accuracy of 0.94. The second step profile distinguished PD cases from other neurodegenerative diseases with a diagnostic accuracy of 0.98. The proteomic profile differed in step 1 versus step 2, suggesting that a multistep proteomic profile algorithm to detecting and distinguishing between neurodegenerative diseases may be optimal. Discussion: These data provide evidence of the potential use of a multitiered blood-based proteomic screening method for detecting individuals with neurodegenerative disease and then distinguishing PD from other neurodegenerative diseases.
KW - Blood biomarkers
KW - Diagnostic accuracy
KW - Parkinson's disease
KW - Precision medicine
KW - Proteomics
UR - http://www.scopus.com/inward/record.url?scp=85065074000&partnerID=8YFLogxK
U2 - 10.1016/j.dadm.2019.03.001
DO - 10.1016/j.dadm.2019.03.001
M3 - Article
AN - SCOPUS:85065074000
VL - 11
SP - 374
EP - 382
JO - Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring
JF - Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring
SN - 2352-8729
ER -